| Wissenschaftl. Titel | Randomized, Controlled, Open-label, Phase 3, Global Multi-Center Trial to Assess the Efficacy and Safety of Zipalertinib plus Chemotherapy versus Chemotherapy alone, in Patients with previously Untreated, Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations |
| Erkrankung |
Thorax:
Nicht-kleinzelliges Lungenkarzinom:
Erstlinie
|
| Molekularer Marker |
EGFR-EGFR ex20ins |
| Kurzprotokoll | Kurzprotokoll |
| Links | Weiterführende Informationen (NIH) |
erstellt 01.08.2024 Data entry III CCP
geändert 22.08.2024 Data entry IX CCP